Study characteristics
| . | No. of articles (%) . |
|---|---|
| Journal | |
| Leukemia & Lymphoma | 5 (17) |
| Pharmacoeconomics | 4 (14) |
| Value in Health | 4 (14) |
| European Journal of Haematology | 3 (10) |
| Acta Oncologica | 2 (7) |
| Cancer | 2 (7) |
| Annals of Internal Medicine | 1 (3) |
| Annals of Oncology | 1 (3) |
| British Journal of Cancer | 1 (3) |
| Other | 6 (21) |
| Country | |
| United States | 9 (31) |
| United Kingdom | 6 (21) |
| Norway | 3 (10) |
| Sweden | 3 (10) |
| France | 2 (7) |
| Canada | 1 (3) |
| Finland | 1 (3) |
| Other | 4 (14) |
| Perspective | |
| Health care payer | 18 (62) |
| Societal | 7 (24) |
| Industry funded | 22 (76) |
| Economic data collected alongside clinical trial | 6 (21) |
| . | No. of articles (%) . |
|---|---|
| Journal | |
| Leukemia & Lymphoma | 5 (17) |
| Pharmacoeconomics | 4 (14) |
| Value in Health | 4 (14) |
| European Journal of Haematology | 3 (10) |
| Acta Oncologica | 2 (7) |
| Cancer | 2 (7) |
| Annals of Internal Medicine | 1 (3) |
| Annals of Oncology | 1 (3) |
| British Journal of Cancer | 1 (3) |
| Other | 6 (21) |
| Country | |
| United States | 9 (31) |
| United Kingdom | 6 (21) |
| Norway | 3 (10) |
| Sweden | 3 (10) |
| France | 2 (7) |
| Canada | 1 (3) |
| Finland | 1 (3) |
| Other | 4 (14) |
| Perspective | |
| Health care payer | 18 (62) |
| Societal | 7 (24) |
| Industry funded | 22 (76) |
| Economic data collected alongside clinical trial | 6 (21) |
The analysis included 29 studies, whose mean quality rating was 4.85 (range 3.5-6.5) ± 0.61 standard deviation.